Price targets

Analyst ratings

4 analysts rated this company in the past 90 days. The average target price is €19.00, this is a change of +31.2% compared to the current price.

• September 26, 2025

  UBS lowers target for Evonik to 15 euros - 'Neutral'

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS lowered its price target for Evonik from €17 to €15, but maintained its rating at "neutral." Analyst Geoff Haire cut his operating profit estimates through 2027 by an average of four percent and his earnings estimates by an average of seven percent on Friday. To achieve the annual operating profit target for 2025, the fourth quarter would have to be at the previous year's level./ag/zb

  Publication of the original study: September 26, 2025 / 6:58 a.m. / GMT

  First distribution of the original study: September 26, 2025 / 6:58 a.m. / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 26, 2025

  JPMorgan lowers target for Evonik to 20 euros - 'Overweight'

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan lowered its price target for Evonik from €21.50 to €20, but maintained its "Overweight" rating. Analyst Chetan Udeshi cut his estimates for the chemical company for the second time this month. In his commentary published on Friday, he responded to the even more significant forecast cut than feared. However, given the favorable valuation, Udeshi maintains his recommendation for the shares./ag/zb

  Publication of the original study: September 26, 2025 / 12:10 AM / BST

  First distribution of the original study: September 26, 2025 / 12:15 AM / BST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 25, 2025

  Berenberg lowers target for Evonik to 16 euros - 'Hold'

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has lowered its price target for Evonik from €18 to €16, but maintained its "Hold" rating. The use of funds must be reconsidered, wrote Sebastian Bray in his commentary on the chemical company's forecast reduction, published Friday. The third quarter was characterized by weakness - across the board./rob/ag/zb

  Publication of the original study: September 25, 2025 / 7:55 p.m. / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 12, 2025

  Berenberg maintains Evonik on 'Hold' - target 18 euros

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg maintained its rating for Evonik at "Hold" with a price target of €18 following a conference on food ingredients and chemicals organized by the private bank. Given similarly subdued business in the third quarter as in the second quarter, many industrially oriented chemical companies have been cautious about issuing positive forecasts, Sebastian Bray wrote in an industry study released Monday. Due to the numerous "false hopes" for a recovery in the second half of 2025, the management teams' current expectations are likely realistic./edh/gl

  Publication of the original study: September 12, 2025 / 4:33 p.m. / GMT. First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 12, 2025

  UBS maintains 'Neutral' rating on Evonik - target 17 euros

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Evonik at "Neutral" with a price target of €17. In an industry study published Monday, Geoff Haire examined the positioning of US investors in the chemicals sector. The focus is on earnings risks for the 2025 fiscal year and potential drivers for an earnings recovery in the coming fiscal year. Investors appeared to doubt the industry's ability to achieve revenue growth and double-digit earnings growth in 2026./tih/gl

  Publication of the original study: September 12, 2025 / 3:37 PM / GMT. First distribution of the original study: September 12, 2025 / 3:37 PM / GMT.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• August 5, 2025

  Berenberg lowers target for Evonik to 18 euros - 'Hold'

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has lowered its price target for Evonik from €20 to €18, but maintained its "Hold" rating. The specialty chemicals group's shares have recently suffered from a disappointing free cash flow, Sebastian Bray wrote in a study published Wednesday. It reduced its revenue and earnings forecasts for 2025 to 2027./rob/edh/mis

  Publication of the original study: August 5, 2025 / 5:13 PM / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• August 1, 2025

  UBS maintains Evonik at 'Neutral' - Target 18 euros

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Evonik at "Neutral" after the company's earnings release, with a price target of €18. Operating profit (EBITDA) and sales in the second quarter were slightly below analyst consensus, Geoff Haire wrote in a study released Friday. The lower end of the EBITDA outlook is now considered more likely. However, the consensus and its estimate would already be at that level at two billion euros./rob/tih/nas

  Publication of the original study: August 1, 2025 / 5:59 a.m. / GMT

  First distribution of the original study: August 1, 2025 / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• July 7, 2025

  UBS lowers target for Evonik to 18 euros - 'Neutral'

  ZURICH (dpa-AFX Analyser) - The Swiss major bank UBS has lowered its price target for Evonik from 20 to 18 euros ahead of second-quarter figures and left the rating at "neutral". In an outlook on Monday, analyst Geoff Haire lowered the chemical company's operating result (EBITDA) and earnings per share estimates for 2025 to 2027 by an average of three percent and two percent, respectively./rob/bek/la

  Publication of the original study: July 7, 2025 / 12:56 PM / GMT

  First distribution of the original study: July 7, 2025 / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• June 4, 2025

  UBS raises target for Evonik to 20 euros - 'Neutral'

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS raised its price target for Evonik from 19 to 20 euros, but left its rating at "neutral." Geoff Haire, in his assessment published Thursday, is not exactly optimistic about the chemicals sector, predicting that 2025 and 2026 will likely be years of low volume growth. He incorporated the first-quarter results into his estimates. Due to the impact of tariffs, it reduced its industry earnings expectations for the coming year to a level below the consensus./tih/ag

  Publication of the original study: June 4, 2025 / 6:15 PM / GMT

  First distribution of the original study: June 4, 2025 / 6:15 PM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• June 2, 2025

  Berenberg maintains Evonik on 'Hold' - target 20 euros

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained its rating for Evonik at "Hold" after the specialty chemicals group's capital markets day, with a price target of €20. Sebastian Bray wrote on Monday evening that the investor event left him with mixed feelings. On the one hand, there is a significant improvement in cash flow resilience, but on the other hand, the outlook for methionine supply after 2025 is not encouraging, and the sale of C4 assets is taking longer than planned./edh/ag

  Publication of the original study: June 2, 2025 / 8:18 p.m. / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• May 27, 2025

  Deutsche Bank Research raises target for Evonik to 25 euros - 'Buy'

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research raised its price target for Evonik from €23 to €25 and maintained its "Buy" rating. The overall message of the recent capital markets day was not revolutionary, wrote Virginie Boucher-Ferte in a study released Tuesday. Rather, the event demonstrated that the specialty chemicals group's transformation is not yet complete and that further benefits can be expected./edh/gl

  Publication of the original study: May 27, 2025 / Time not specified in the study / CET. First distribution of the original study: May 27, 2025 / 7:51 a.m. / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• May 23, 2025

  UBS maintains 'Neutral' rating on Evonik - Target 19 euros

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Evonik at "Neutral" with a price target of €19. Investors are currently looking for safety, which is rare in the chemicals sector, analyst Geoff Haire wrote on Friday afternoon. Meanwhile, investors are questioning potential downside risks in the cyclical sector, with BASF being the generally preferred alternative. However, economic stimulus programs and capacity cuts are not yet a reason to generally invest in cyclical stocks./tih/ag

  Publication of the original study: May 23, 2025 / 4:50 PM / GMT

  First distribution of the original study: May 23, 2025 / 4:50 PM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• May 13, 2025

  Deutsche Bank Research maintains Evonik's 'Buy' rating - target €23

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its "Buy" rating for Evonik following the company's earnings release, with a price target of €23. Virginie Boucher-Ferte, in a study released Tuesday, attested to the chemical company's solid first quarter performance. This roughly underpins consensus estimates. Unlike some competitors, Evonik now views the economic environment somewhat more conservatively, but the outlook was nevertheless confirmed. This reflects the robust business with the animal feed protein methionine./tih/mis

  Publication of the original study: May 13, 2025 / Time not specified in the study / CET

  First distribution of the original study: May 13, 2025 / 8:00 a.m. / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• May 12, 2025

  UBS maintains 'Neutral' rating on Evonik - Target 19 euros

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Evonik at "Neutral" after the company's earnings release, with a price target of €19. Operating results exceeded expectations in the first quarter, Geoff Haire wrote on Monday. The annual targets remain unchanged./rob/ag/gl

  Publication of the original study: May 12, 2025 / 05:59 / GMT. First distribution of the original study: May 12, 2025 / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• April 4, 2025

  UBS raises target for Evonik to 19 euros - 'Neutral'

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS raised its price target for Evonik from 18 to 19 euros and maintained its rating at "neutral." The first quarter provided little sign of a recovery in the overall economic environment, wrote analyst Geoff Haire in a report on European chemical stocks published Monday. Data and company commentary pointed to a decline in demand in the US in March, which is likely to have been partially offset by a recovery in China. German economic stimulus and the EU Clean Industrial Deal are longer-term positive aspects. For Evonik, he raised his estimates for operating profit in 2025 and earnings per share from 2025 to 2027, citing higher sales volumes and slightly higher prices./ck/he

  Publication of the original study: April 4, 2025 / 9:55 PM / GMT. First distribution of the original study: April 4, 2025 / 9:55 PM / GMT.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• April 2, 2025

  Berenberg raises target for Evonik to 20 euros - 'Hold'

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg raised its price target for Evonik from €18 to €20, but maintained its "Hold" rating. The chemical company's reputation as a strong cash siphoner has partially shielded the shares from the industry sell-off of the past two weeks due to US tariff policy, wrote analyst Sebastian Bray in his commentary published Thursday. This is understandable, especially since the coming weeks are likely to reveal the benefits of the German infrastructure financing package for the industry. However, no company-specific drivers for an above-average share price performance are in sight for the next four to six months./gl/ag

  Publication of the original study: April 2, 2025 / 4:25 p.m. / GMT. First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• March 6, 2025

  Deutsche Bank Research raises target for Evonik to 24 euros - 'Buy'

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research raised its price target for Evonik from €21 to €24 and maintained its "Buy" rating. The past fiscal year and the outlook for the current first quarter imply upside potential for estimates, wrote analyst Virginie Boucher-Ferte in her review of the fourth-quarter results released Thursday. This puts the specialty chemicals manufacturer in stark contrast to the rest of the industry./bek/ag

  Publication of the original study: March 6, 2025 / Time not specified in the study / CET

  First distribution of the original study: March 6, 2025 / 8:10 a.m. / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• March 5, 2025

  Goldman maintains Evonik at 'Neutral' - Target 20 euros

  NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has maintained its rating for Evonik at "Neutral" with a price target of €20. The specialty chemicals group's fourth quarter was disappointing, but the signals for the first quarter underpin its full-year targets for 2025, analyst Georgina Fraser wrote on Wednesday after the results./ag/edh

  Publication of the original study: March 5, 2025 / 7:00 a.m. / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• March 5, 2025

  UBS maintains Evonik at 'Neutral' - Target 18 euros

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Evonik at "Neutral" following fourth-quarter results, with a price target of €18. The forecast for operating profit (EBITDA) in 2025 is in line with market expectations, analyst Geoff Haire wrote on Wednesday. The statements for the current first quarter are better than the previous outlook of comparable companies./bek/ag

  Publication of the original study: March 5, 2025 / 7:14 a.m. / GMT

  First distribution of the original study: March 5, 2025 / 7:14 a.m. / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• March 5, 2025

  JPMorgan maintains Evonik at 'Overweight' - target 25 euros

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Evonik at "Overweight" following fourth-quarter results, with a price target of €25. Analyst Chetan Udeshi assessed these results as weaker than expected in his initial reaction on Wednesday. The specialty chemicals group's adjusted operating result (EBITDA) fell short of its own and the consensus estimate by 20 to 25 percent. However, the forecasts for the current first quarter should provide investor confidence, even compared to competitors from Europe and the US./bek/ag

  Publication of the original study: March 5, 2025 / 7:10 a.m. / GMT

  First distribution of the original study: March 5, 2025 / 7:10 a.m. / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 24, 2025

  Berenberg maintains Evonik on 'Hold' - target 18 euros

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained a "Hold" rating on Evonik with a price target of €18. For investors in European chemical stocks, there are two ways to "wait and see," especially with regard to diversified chemical companies, analyst Sebastian Bray wrote in an industry report published Monday. He sees a short wait in view of a possible imminent revaluation. He cited fiscal stimulus in the US and China, more modest US tariffs than feared, and new political support for the chemical industry in Germany and China as reasons. Bray expects a waiting period beyond 2025 until profits can benefit again from lower energy costs in Europe or reforms in Germany that promote competitiveness./ck/tih

  Publication of the original study: January 24, 2025 / 6:03 p.m. / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 3, 2025

  UBS maintains Evonik at 'Neutral' - Target 18 euros

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Evonik at "Neutral" with a price target of €18. Analyst Geoff Haire wrote in an industry report released Monday that 2025 will be more uncertain in the chemicals sector than 2024, which was characterized by a lack of inventory buildup by customers and the beginning of portfolio adjustments by companies. In 2025, the focus will once again be on the prospects for a recovery in demand, but investors should also pay attention to geopolitics – with the US-China relationship and the political environment in Germany and France. In a difficult environment, companies could respond with further cost reductions. Potential positive drivers include government stimulus measures in Germany, the resumption of Russian gas supplies to Europe, and the reconstruction of Ukraine. Overall, the expert prefers defensive subsectors within the industry: consumer chemicals and industrial gas suppliers./mis/bek

  Publication of the original study: January 3, 2025 / 11:38 PM / GMT

  First distribution of the original study: January 3, 2025 / 11:38 PM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 1, 2025

  Berenberg lowers target for Evonik to 18 euros - 'Hold'

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has lowered its price target for Evonik from €20 to €18 and maintained its "Hold" rating. Analyst Sebastian Bray reduced his estimates for the chemical company's operating result (EBIT) for 2024 to 2026 in a study published Thursday. A higher tax burden may have impacted 2024. In addition, there is a threat of increased competition in the adhesives chemicals business./bek/gl

  Publication of the original study: January 1, 2025 / 6:00 PM / GMT. First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• December 19, 2024

  Warburg Research raises target for Evonik to 24 euros - 'Buy'

  HAMBURG (dpa-AFX Analyst) - The analyst firm Warburg Research has raised its price target for Evonik from €23 to €24 and maintained its rating at "Buy." In his outlook for the specialty chemicals group's fourth-quarter report, published Thursday, analyst Oliver Schwarz anticipates the usual seasonal slowdown. He anticipates fairly moderate growth targets for 2025./ag/ck

  Publication of the original study: December 19, 2024 / 8:15 a.m. / CET

  First distribution of the original study: Date not specified in study / Time not specified in study / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• December 17, 2024

  UBS lowers target for Evonik to 18 euros - 'Neutral'

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has lowered its price target for Evonik from €22 to €18, but left its rating at "Neutral." Analyst Geoff Haire's forecast for fourth-quarter operating profit (EBITDA) is 6 percent below consensus. He wrote this on Tuesday evening in his outlook for the March 5 report./ag/edh

  Publication of the original study: December 17, 2024 / 5:59 PM / GMT

  First distribution of the original study: December 18, 2024 / 5:59 PM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• December 16, 2024

  Goldman raises target for Evonik to 20 euros - 'Neutral'

  NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs raised its price target for Evonik from €19 to €20, but maintained its rating at "Neutral." Analyst Georgina Fraser adjusted her estimates on Monday in her outlook for the quarterly report. Among other things, she cut the expenditure estimate./ag/zb

  Publication of the original study: December 16, 2024 / 5:07 PM / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• December 8, 2024

  UBS maintains Evonik at 'Neutral' - Target 22 euros

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Evonik at "Neutral" with a price target of €22. One of the most discussed topics in the European chemical industry is the question of what would happen if Russian gas flowed heavily to Europe again, wrote analyst Geoff Haire in an industry study published Monday. A ceasefire between Russia and Ukraine would reduce the risk premium, lead to increased exports, and thus to significantly lower gas prices. In the chemicals sector, BASF, Covestro, Lanxess, and to a certain extent Yara would benefit the most./edh/mis

  Publication of the original study: December 8, 2024 / 5:33 PM / GMT

  First distribution of the original study: December 8, 2024 / 5:33 PM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• December 2, 2024

  JPMorgan maintains Evonik at 'Overweight' - target 25 euros

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained an "overweight" rating on Evonik with a price target of €25. Earnings and valuations of the cyclical European chemical company remain low, and the economic outlook remains mixed, even in light of possible US tariffs under Donald Trump, analyst Chetan Udeshi wrote in his industry outlook published Monday. Accordingly, short-term earnings momentum is likely to remain negative. However, he is more confident than the market consensus regarding Evonik's operating result (EBIT) in 2025.

  Publication of the original study: December 2, 2024 / 1:13 a.m. / GMT. First distribution of the original study: December 2, 2024 / 1:18 a.m. / GMT.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 15, 2024

  Goldman lowers target for Evonik to 19 euros - 'Neutral'

  NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs lowered its price target for Evonik from €19.90 to €19, but maintained its rating at "Neutral." Analyst Georgina Fraser adjusted her estimates on Friday morning to reflect the latest quarterly report. She also took current currency developments into account./ag/tih

  Publication of the original study: November 15, 2024 / 9:16 a.m. / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 7, 2024

  Deutsche Bank Research maintains Evonik's 'Buy' rating - target €25

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its "Buy" rating for Evonik following its quarterly results, with a price target of €25. The specialty chemicals group's operating result (EBITDA) was "in line," wrote analyst Virginie Boucher-Ferte in a study published Thursday./edh/gl

  Publication of the original study: November 7, 2024 / Time not specified in study / CET. First distribution of the original study: November 7, 2024 / 8:05 a.m. / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 6, 2024

  UBS maintains Evonik at 'Neutral' - Target 22 euros

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Evonik at "Neutral" with a price target of €22. Analyst Geoff Haire expects a neutral price reaction to the quarterly report on Wednesday morning. In the current environment, a strong cash inflow and confirmed targets are nevertheless positive./ag/gl

  Publication of the original study: November 6, 2024 / 8:11 a.m. / GMT First distribution of the original study: November 6, 2024 / 8:11 a.m. / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 6, 2024

  JPMorgan maintains Evonik at 'Overweight' - target 25 euros

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Evonik at "Overweight" with a price target of €25. Analyst Chetan Udeshi believes the negative price reaction to the quarterly report is exaggerated, according to his commentary on Wednesday evening. Compared to others in the industry, the hurdle rate for market expectations for 2025 is quite low./ag/gl

  Publication of the original study: November 6, 2024 / 9:35 PM / GMT. First distribution of the original study: November 7, 2024 / 12:15 AM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 6, 2024

  Warburg Research maintains Evonik's 'Buy' rating - target €23

  HAMBURG (dpa-AFX Analyst) - Following Evonik's quarterly results, the analyst firm Warburg Research has maintained a "Buy" rating with a price target of €23. The specialty chemicals group has met expectations and confirmed its outlook, analyst Oliver Schwarz wrote in an initial reaction on Wednesday. The only confirmed target range for adjusted operating profit (EBITDA) seems somewhat odd given what has already been achieved after nine months./gl/edh

  Publication of the original study: November 6, 2024 / 8:15 a.m. / CET. First distribution of the original study: Date not specified in study / Time not specified in study / CET.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 6, 2024

  JPMorgan maintains Evonik at 'Overweight' - target 25 euros

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Evonik at "Overweight" with a price target of €25. The third quarter slightly exceeded expectations, wrote analyst Chetan Udeshi on Wednesday morning after the company's results. However, the consensus for the fourth quarter is likely to decline slightly./ag/gl

  Publication of the original study: November 6, 2024 / 6:30 a.m. / GMT First distribution of the original study: / / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 6, 2024

  Jefferies maintains Evonik at 'Hold' - target 21 euros

  NEW YORK (dpa-AFX Analyst) - Following the third-quarter results, analyst Jefferies has maintained its "Hold" rating for Evonik with a price target of €21. Analyst Chris Counihan expects a subdued share price reaction following the specialty chemicals group's figures, according to a quick assessment released Wednesday. Although Evonik's operating result performed slightly better than he and the consensus had expected, it fell short in terms of group sales./ck/gl

  Publication of the original study: November 6, 2024 / 1:02 a.m. / ET First distribution of the original study: November 6, 2024 / 1:02 a.m. / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• October 17, 2024

  Warburg Research maintains Evonik's 'Buy' rating - target €23

  HAMBURG (dpa-AFX Analyst) - Ahead of third-quarter results, analyst Warburg Research has maintained its "Buy" rating for Evonik with a price target of €23. Analyst Oliver Schwarz expects solid results from the specialty chemicals group in a study released Thursday. Adjusted operating profit (EBITDA) should be almost at the previous quarter's level, thanks primarily to the robust business with the animal feed protein methionine. The only fly in the ointment is likely the Performance Materials division, which is no longer part of the core business and is likely to continue to struggle with weak demand./mis/bek

  Publication of the original study: October 17, 2024 / Time not specified in the study / CEST

  First distribution of the original study: October 17, 2024 / 8:15 a.m. / CEST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• October 14, 2024

  Deutsche Bank Research maintains Evonik's 'Buy' rating - target €26

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its "Buy" rating for Evonik with a price target of €26. The announced streamlining of the Coating & Adhesive Resins and Health Care business units is another small step toward improving the chemical company's business portfolio, wrote analyst Virginie Boucher-Ferte in a study released Monday. The company's management's commitment to improving growth and profitability is underscored./mis/ajx

  Publication of the original study: October 14, 2024 / Time not specified in the study / CET

  First distribution of the original study: October 14, 2024 / 8:08 a.m. / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 12, 2024

  Berenberg maintains Evonik on 'Hold' - target 20 euros

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained its "Hold" rating for Evonik with a price target of €20. "Some are happy and many are hopeful," wrote analyst Sebastian Bray in his commentary on a chemical industry conference on Friday. Covestro emphasized how quickly a recovery could come, especially after a long period of low margins. However, after the conference, Bray feels it will take several more months for things to improve./ag/la

  Publication of the original study: September 12, 2024 / 5:00 PM / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 8, 2024

  JPMorgan maintains Evonik at 'Overweight' - target 25 euros

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained an "overweight" rating on Evonik with a price target of €25. Following a webinar with CEO Christian Kullmann, analyst Chetan Udeshi raised his estimates for the specialty chemicals group's sales and adjusted earnings. He wrote this in his commentary published on Monday. Kullmann highlighted a leaner and more efficient cost structure, further progress in portfolio optimization, and a continued focus on innovation as medium-term priorities. Evonik is apparently defying the weak industry environment thanks to self-help measures./gl/ag

  Publication of the original study: September 8, 2024 / 4:36 PM / BST First distribution of the original study: September 9, 2024 / 12:15 AM / BST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 6, 2024

  UBS maintains 'Neutral' rating on Evonik - Target 19 euros

  ZURICH (dpa-AFX Analyst) - Following a conference held by the major Swiss bank, UBS maintained its rating for Evonik at "Neutral" with a price target of €19. The volume outlook was consistently the focus of the discussions, wrote analyst Geoff Haire in his industry commentary on chemical stocks published on Monday. Most companies reported modest progress in the third quarter and anticipated normal seasonality in the final quarter. Clients are currently continuing to pay attention to low inventory levels. There are signs of improvement in some areas, but there are downside risks to the business in the automotive sector./tih/ag

  Publication of the original study: September 6, 2024 / 7:21 PM / GMT

  First distribution of the original study: September 6, 2024 / 7:21 PM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 5, 2024

  Barclays maintains Evonik at 'Overweight' - target 25 euros

  LONDON (dpa-AFX Analyser) - The British investment bank Barclays has maintained its rating for Evonik at "Overweight" with a price target of 25 euros. The recent development of petrochemical spreads – the price difference between raw material and sold product – certainly signals a growing risk to some corporate targets in the industry, wrote analyst Alex Stewart in an industry report released Friday./mis/tih

  Publication of the original report: September 5, 2024 / 4:29 PM / GMT

  First distribution of the original report: September 6, 2024 / 3:00 AM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• August 11, 2024

  UBS lowers target for Evonik to 19 euros - 'Neutral'

  ZURICH (dpa-AFX Analyst) - UBS has lowered its price target for Evonik from 20 to 19 euros and left its rating at "Neutral." Increased inventories in the first half of the year are likely to put further pressure on volumes at European chemical companies, analyst Geoff Haire wrote in an industry report released Monday. He lowered his estimate for volume growth in the sector overall for the second half of the year by one percentage point. He expects the strongest growth in the consumer chemicals sector, while the agricultural and industrial gases sectors are likely to see the weakest. The latest key macro indicators in China, Europe, and the US remain in contraction territory. He justified the reduced price target for Evonik with the lower valuation of the peer group./ck/ajx

  Publication of the original study: August 11, 2024 / 3:12 AM / GMT

  First distribution of the original study: August 11, 2024 / 3:12 AM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.